Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEs/ARBs) have proven benefit for patients with myocardial infarction and heart failure; their use is a core measure of hospital quality for the Centers for Medicare and Medicaid Services. The authors’ urban medical center has lower-than-average performance on this measure. The authors used published best practices to design and implement a comprehensive strategy to improve ACE/ARB performance with existing decision support and human resources. Chart reminders were targeted to providers of patients eligible for ACEs/ARBs but not receiving them. ACE/ARB performance increased 8.5% in postintervention patients compared with historical controls. The increase was 20.7% among patients not on ACEs/ARBs on admission (P =.03). Chronic kidney disease (CKD) was inversely associated with the effectiveness of the intervention. A comprehensive strategy can be effective in narrowing the performance gap even for populations with a high prevalence of CKD. However, future work is needed to improve performance among patients whose ACEs/ARBs are withheld during hospitalization.
Office of the Federal Register, National Archives and Records Administration. Medicare program: changes to the hospital inpatient prospective payment systems and fiscal year 2006 rates. Fed Regist. 2005;70:47420.
2.
AntmanEMHandMArmstrongPW. 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 writing committee. Circulation. 2008;117:296-329.
3.
GargRYusufS. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450-1456.
4.
AslamFHaqueAHaqueJJosephJ. Heart failure in subjects with chronic kidney disease: best management practices. World J Cardiol. 2010;2:112-117.
5.
EzekowitzJMcAlisterFAHumphriesKH. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587-1592.
6.
TokmakovaMPSkaliHKenchaiahS. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival and Ventricular Enlargement (SAVE) study. Circulation. 2004;110:3667-3673.
Office of the Federal Register, National Archives and Records Administration. Medicare and Medicaid programs: electronic health record incentive program. Fed Regist. 2010;75:44370.
9.
Office of the Federal Register, National Archives and Records Administration. Medicare program: Medicare shared savings program: accountable care organizations. Fed Regist. 2011;76:19570.
10.
KrantzMJBakerWAEstacioRO. Comprehensive coronary artery disease care in a safety-net hospital: results of Get With the Guidelines quality improvement initiative. J Manag Care Pharm. 2007;13:319-325.
11.
MehtaRHMontoyeCKGalloglyM. Improving quality of care for acute myocardial infarction: the Guidelines Applied in Practice (GAP) initiative. JAMA. 2002;287:1269-1276.
12.
Agency for Healthcare Research and Quality. Concurrent and retrospective chart review, performance reporting, and other support significantly improve adherence to core measures in four clinical areas. http://www.innovations.ahrq.gov/content.aspx?id=2688. Accessed April 15, 2011.
13.
Agency for Healthcare Research and Quality. Alerts, standing orders, and care pathways boost quality of care for pneumonia, heart attack, and heart failure. http://www.innovations.ahrq.gov/content.aspx?id=1750. Accessed April 15, 2011.
14.
Agency for Healthcare Research and Quality. Comprehensive heart failure program enhances adherence to recommended care and reduces hospital readmissions. http://www.innovations.ahrq.gov/content.aspx?id=2214. Accessed April 15, 2011.
15.
Agency for Healthcare Research and Quality. Formal structures and processes promote system-wide focus on core measures, leading to significantly better performance. http://www.innovations.ahrq.gov/content.aspx?id=2955. Accessed April 15, 2011.
16.
Agency for Healthcare Research and Quality. Multidisciplinary team redesigns care processes and systems, leading to significantly improved performance on core measures in four clinical areas. http://www.innovations.ahrq.gov/content.aspx?id=3051. Accessed April 15, 2011.
17.
Agency for Healthcare Research and Quality. Formal processes ensure system-wide focus on heart attack, heart failure, pneumonia, and surgical care, improving performance on core measures. http://www.innovations.ahrq.gov/content.aspx?id=3055. Accessed April 15, 2011.
Hospital Interventions Quality Improvement Organization Support Center. ACE-inhibitor and ARB contraindication/intolerance for discharges effective April 1, 2007. jeny.ipro.org/attachment.php?attachmentid=2132&d=1169733791. Accessed August 5, 2011.
20.
Office of the Federal Register, National Archives and Records Administration. Medicare program; hospital inpatient value-based purchasing program. Fed Regist. 2011;76: 26493-26499.
